Clinical Trial Update: [S,S]-Reboxetine Long Term Safety Study In Post-Shingles Pain. [Phase 2]

View source ↗

Summary

Pfizer-sponsored Phase 2 long-term safety study of S,S-Reboxetine in postherpetic neuralgia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postherpetic Neuralgia

Drugs mentioned

• S,S-Reboxetine (reboxetine)

Snippet

Sponsor: Pfizer | Conditions: Pain | Phase 2 | Status: TERMINATED